Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Change in Cash (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Change in Cash for 11 consecutive years, with $4.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash rose 577.66% year-over-year to $4.5 million, compared with a TTM value of -$128120.0 through Sep 2025, down 154.06%, and an annual FY2024 reading of $1.3 million, up 137.62% over the prior year.
  • Change in Cash was $4.5 million for Q3 2025 at Kiora Pharmaceuticals, up from -$2.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $28.8 million in Q1 2024 and bottomed at -$24.7 million in Q2 2024.
  • Average Change in Cash over 5 years is $211330.0, with a median of -$2.2 million recorded in 2023.
  • Peak annual rise in Change in Cash hit 1215.57% in 2024, while the deepest fall reached 645.81% in 2024.
  • Year by year, Change in Cash stood at -$3.3 million in 2021, then increased by 14.29% to -$2.8 million in 2022, then dropped by 5.68% to -$2.9 million in 2023, then skyrocketed by 37.36% to -$1.8 million in 2024, then skyrocketed by 342.83% to $4.5 million in 2025.
  • Business Quant data shows Change in Cash for KPRX at $4.5 million in Q3 2025, -$2.7 million in Q2 2025, and -$21274.0 in Q1 2025.